A judge has expressed frustration over the fourth discovery fight this year in Fortescue’s trade secrets case against Element Zero, as the green iron startup claims its bigger rival is trying to drag out the litigation.
Regeneron and Bayer have lost their bid to block generic drug maker Sandoz from launching a biosimilar of their blockbuster eye drug Eylea.
Explosives company Dyno Nobel is appealing a court’s dismissal of its case seeking to invalidate patents owned by rival Orica for a wireless detonation device.
Dyno Nobel has lost its bid to invalidate three of explosive manufacturer Orica’s patents for a wireless detonation device, with a judge finding it was liable for patent infringement.
Two proponents of Bitcoin Cash have battled before IP Australia over the trade mark ‘Bitcoin Cash City’, with one claiming he coined it in a text message in 2019.
US biotech company Regeneron Pharmaceuticals has sued Sandoz, claiming it is threatening to infringe the patent for its Eylea biologic, used to treat macular degeneration and diabetic macular oedema.
Green iron start-up Element Zero has said it will fight Fortescue’s bid to access nearly nine million documents collected under a controversial search order in the mining giant’s case alleging former employees misappropriated its process for carbon dioxide-free iron.
US lab products giant Beckman Coulter has successfully opposed an Australian biotech’s bid to trade mark ‘Cytophex’ for its stem cell expansion system, with an IP Australia delegate finding the mark is too similar to Beckman’s ‘CytoFLEX’ mark.
Green iron start-up Element Zero has lost its latest bid to set aside search orders in a case by Fortescue alleging former employees misappropriated its process for carbon dioxide-free iron.
The High Court won’t hear Bayer’s appeal of an invalidity finding over patents for blood thinner Xarelto, despite the company’s claim the decision has “profound” consequences for drug R&D.